Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients

Liisa M Pelttari1, Riikka Nurminen2, Alexandra Gylfe3, Lauri A Aaltonen3, Johanna Schleutker24 and Heli Nevanlinna1*

Author Affiliations

1 Departments of Obstetrics and Gynecology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland

2 Institute of Biomedical Technology/BioMediTech, University of Tampere and Fimlab Laboratories, Tampere, Finland

3 Department of Medical Genetics, Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland

4 Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland

For all author emails, please log on.

BMC Cancer 2012, 12:552  doi:10.1186/1471-2407-12-552

Published: 23 November 2012

Abstract

Background

Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied.

Methods

To study the role of RAD51C mutations in other common cancer types, we genotyped the Finnish RAD51C founder mutations c.837 + 1G > A and c.93delG in 1083 prostate cancer patients and 802 colorectal cancer patients using TaqMan Real-Time PCR.

Results

No RAD51C mutations c.837 + 1G > A or c.93delG were detected among the prostate or colorectal cancer patients.

Conclusions

The results suggest that the RAD51C mutations do not predispose to prostate or colorectal cancer.

Keywords:
RAD51C; Prostate cancer; Colorectal cancer; Breast cancer; Ovarian cancer; Founder mutation